Denosumab
- Generic Name
- Denosumab
- Brand Names
- Prolia, Xgeva, Wyost, Jubbonti
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 615258-40-7
- Unique Ingredient Identifier
- 4EQZ6YO2HI
- Background
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and...
- Indication
Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It reduces the incidence of vertebral, nonvertebral, and hip fractures. Prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. It can also be use...
- Associated Conditions
- Bone Fractures, Bone Giant Cell Tumor, Bone Loss, Bone pain, Spinal Cord Compression, Bone destruction, High risk of fracture Osteoporosis, Refractory Hypercalcemia of malignancy
- Associated Therapies
- -
RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Prince of Wales Hospital, Shatin, Hong Kong
- Target Recruit Count
- 120
- Registration Number
- NCT06643780
- Locations
- 🇨🇳
The Chinese University of Hong Kong, Hong Kong, China
Denosumab for Type 1 Diabetes
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 45
- Registration Number
- NCT06524960
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
Romosozumab Versus Denosumab in GIOP: a 2-year Extension Study
- Conditions
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Tuen Mun Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT06472050
- Locations
- 🇨🇳
Department of Medicine, Tuen Mun Hospital, Hong Kong, China
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
- Conditions
- Interventions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 152
- Registration Number
- NCT06374459
- Locations
- 🇺🇸
The University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 8
- Registration Number
- NCT06357741
- Locations
- 🇨🇳
Wuhan Union Hospital, Wuhan, Hubei, China
Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease
- Conditions
- Interventions
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 478
- Registration Number
- NCT06314698
NAPO - Novel Approach for Oligospermia
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Martin Blomberg Jensen
- Target Recruit Count
- 42
- Registration Number
- NCT06300229
- Locations
- 🇩🇰
Division of Translational Endocrinology, Department of Endocrinology and Internal Medicine, Copenhagen, Denmark
Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients
- Conditions
- Interventions
- First Posted Date
- 2024-02-22
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 340
- Registration Number
- NCT06272227
- Locations
- 🇰🇷
Division of Endocrinology, Department of internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea, Republic of
Sequential Therapies After Osteoanabolic Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- 424 General Military Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT06164795
- Locations
- 🇩🇪
Department of Medicine III and Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany
🇬🇷251 Airforce & VA General Hospital, Athens, Greece
🇬🇷424 General Military Hospital, Thessaloniki, Greece
Comparison of Efficacy of Denosumab With Eldecalcitol or Native Vitamin D in Postmenopausal Women With Osteoporosis.
- Conditions
- Interventions
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Xi'an Honghui Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05884372
- Locations
- 🇨🇳
Zeng,Yuhong, Xi'an, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.